MX2020005916A - Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido. - Google Patents

Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.

Info

Publication number
MX2020005916A
MX2020005916A MX2020005916A MX2020005916A MX2020005916A MX 2020005916 A MX2020005916 A MX 2020005916A MX 2020005916 A MX2020005916 A MX 2020005916A MX 2020005916 A MX2020005916 A MX 2020005916A MX 2020005916 A MX2020005916 A MX 2020005916A
Authority
MX
Mexico
Prior art keywords
amylin
aqueous solution
receptor agonist
copolyamino acid
injectable aqueous
Prior art date
Application number
MX2020005916A
Other languages
English (en)
Inventor
Alexandre Geissler
Richard Charvet
You-Ping Chan
Romain Noel
Nicolas Laurent
Original Assignee
Adocia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1761808A external-priority patent/FR3074682B1/fr
Priority claimed from FR1855943A external-priority patent/FR3083085B1/fr
Application filed by Adocia filed Critical Adocia
Publication of MX2020005916A publication Critical patent/MX2020005916A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a una composición en forma de una solución acuosa inyectable, para la cual el pH está comprendido de 6.0 a 8.0, que comprende al menos: a) amilina, un agonista del receptor de amilina o un análogo de amilina; b) un copoliaminoácido con cargas de carboxilato y radicales hidrofóbicos Hy, dicho copoliaminoácido está constituido por unidades glutámicas o aspárticas y dichos radicales hidrofóbicos -Hy se seleccionan de acuerdo con la fórmula X como se define a continuación: C9 (ver formula) Fórmula X caracterizada por que la composición no comprende insulina basal para la cual el punto isoeléctrico IP está comprendido de 5.8 a 8.5. También se refiere a una composición caracterizada por que también comprende una insulina prandial.
MX2020005916A 2017-12-07 2018-12-07 Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido. MX2020005916A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762606139P 2017-12-07 2017-12-07
FR1761808A FR3074682B1 (fr) 2017-12-07 2017-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR1855943A FR3083085B1 (fr) 2018-06-29 2018-06-29 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
PCT/EP2018/083943 WO2019110788A1 (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide

Publications (1)

Publication Number Publication Date
MX2020005916A true MX2020005916A (es) 2020-10-19

Family

ID=66751321

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005916A MX2020005916A (es) 2017-12-07 2018-12-07 Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.

Country Status (6)

Country Link
US (1) US20210401943A1 (es)
IL (1) IL275146B1 (es)
MX (1) MX2020005916A (es)
PH (1) PH12020550804A1 (es)
SA (1) SA520412138B1 (es)
WO (1) WO2019110788A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4091625A1 (en) 2021-05-22 2022-11-23 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4342486A1 (en) 2022-09-20 2024-03-27 Adocia Compositions comprising at least an insulin and an amylin receptor agonist for treating diabetes, in a patient/person having a bmi of more than 28 kg/m² and/or an hba1c of more than 7.6 %

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US6114304A (en) 1993-09-07 2000-09-05 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
WO2007104786A1 (en) 2006-03-15 2007-09-20 Novo Nordisk A/S Mixtures of amylin and insulin
FR2910318B1 (fr) * 2006-12-20 2009-07-03 Flamel Technologies Sa Dispersion de polyaminoacides dans une phase lipidique continue.
EP2173407B1 (en) 2007-07-02 2020-02-19 Roche Diabetes Care GmbH A device for drug delivery
CN103930096B (zh) 2011-10-31 2017-05-31 Xeris药物公司 用于治疗糖尿病的制剂
US9198971B2 (en) * 2012-01-09 2015-12-01 Adocia Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
FR2985428B1 (fr) * 2012-01-09 2016-05-27 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
WO2018122278A1 (fr) 2016-12-27 2018-07-05 Adocia Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide

Also Published As

Publication number Publication date
IL275146A (en) 2020-07-30
SA520412138B1 (ar) 2023-03-16
WO2019110788A1 (fr) 2019-06-13
US20210401943A1 (en) 2021-12-30
PH12020550804A1 (en) 2021-05-31
IL275146B1 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
PH12020550804A1 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
WO2019110797A8 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
SA518400588B1 (ar) محلول قابل للحقن عند الرقم الهيدروجيني 7يشتمل على أنسولين قاعدي واحد على (pi)الأقل تتراوح نقطة التعادل الكهربائي الخاصة به من5.8إلى8.5وحمض بولي أميني مشترك يحمل شحنات كربوكسيلات وجذور كارهة للماء
SG11201810901VA (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid
SA520412141B1 (ar) محلول قابل للحقن عند الرقم الهيدروجيني 7 يشتمل على إنسولين قاعدي واحد على الأقل يتراوح الخاص به بين 5.8 و8.5 وحمض بولي أمينو مشترك حامل لشحنات pi كربوكسيلات وشقوق غير قابلة للذوبان في الماء
SA520412142B1 (ar) محلول قابل للحقن برقم هيدروجيني 7 يبلغ 7 يشتمل على إنسولين قاعدي واحد على الأقل له بين 5.8 و8.5 وحمض بولي أمينو مشترك حامل لشحنات كربوكسيلات وشقوق غير قابلة للذوبان في الماء
MX2016002636A (es) Polipeptido para la escision hidrolitica de la zearalenona y/o derivados de la zearalenona, polinucleotido aislado de la misma y polieptido que contiene aditivo, uso y procedimiento de los mismos.
MX370407B (es) Mejoradores de palatabilidad que comprenden reactivos amino y compuestos de carbonilo para uso en alimento para gatos.
PH12020550828A1 (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
MX2017006900A (es) Solucion acuosa que contiene una combinacion de agentes formadores de complejos.
SG11202005322RA (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
BR112015020895A2 (pt) composto de siloxano substancialmente linear, terminado em amina e produtos époxi feitos com o mesmo
EA202091201A1 (ru) Композиции в форме инъецируемого водного раствора, содержащие амилин, агонист рецептора амилина или аналог амилина и сополиаминокислоту
FR3061023B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
BRPI0907714B8 (pt) Dispersões agrícolas compreendendo oligômeros ou polímeros metálicos
MX2020006670A (es) Composicion acuosa que comprende acido 2-(dimetil-1h-pirazol-1-il) succinico y amoniaco.
FR3074682B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3074680B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
SG11201804902UA (en) A composition for improving memory, learning ability, and cognitive ability
MX2017001900A (es) Composicion nasal con capacidades de formacion de pelicula.
EA202091387A1 (ru) Композиции в форме инъецируемого водного раствора, содержащие человеческий глюкагон и сополиаминокислоту
FR3072875B1 (fr) Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
UA125589U (uk) Композиція для естетичних ін'єкцій
MX2018012428A (es) Composicion para estabilizacion hidrolitica de poliester.
MY155338A (en) Novel insulin derivatives having an extremely delayed time-action profile